Eshelman Ventures
Eshelman Ventures LLC is a private investment firm founded by Fred Eshelman that concentrates on investments in healthcare and healthcare-related companies. The firm follows a participatory, active-investment approach, typically taking board seats in larger investments and assisting portfolio companies with growth and strategy. Investment activity spans angel investing, co-investing alongside VC and private equity funds, academic spinouts and public companies.
Eshelman Ventures
Wilmington, North Carolina, United States, North America
Services
Direct equity and co-investments
Provides capital through angel investments, co-investing alongside venture capital funds, and investments in private equity (primary and secondary) and public companies.
Board participation and strategic guidance
Regularly takes board seats on larger investments and provides active involvement in company growth and strategy.
Operational and management support
Assists portfolio companies in professionalizing management and advising on recruitment of experienced management where founders are primarily technical.
Direct equity and co-investments
Provides capital through angel investments, co-investing alongside venture capital funds, and investments in private equity (primary and secondary) and public companies.
Board participation and strategic guidance
Regularly takes board seats on larger investments and provides active involvement in company growth and strategy.
Operational and management support
Assists portfolio companies in professionalizing management and advising on recruitment of experienced management where founders are primarily technical.
Portfolio
Developing small molecule CDK inhibitors, focusing on a selective CDK2 inhibitor for tumors insensitive to CDK4/6 inhibition.
#Pharmaceuticals / Oncology
Builds biotech companies from the ground up, partnering with biologists and physicians.
#Biotechnology / Company formation
Focused on company formation and venture growth in transformative medicines.
#Biotechnology / Company formation & venture growth
Developing small molecule CDK inhibitors, focusing on a selective CDK2 inhibitor for tumors insensitive to CDK4/6 inhibition.
#Pharmaceuticals / Oncology
Builds biotech companies from the ground up, partnering with biologists and physicians.
#Biotechnology / Company formation
Focused on company formation and venture growth in transformative medicines.
#Biotechnology / Company formation & venture growth